Brucella proline racemase protein A targets Tpl2 to promote IL-10 secretion for establishment of chronic infection - Summary - MDSpire

Brucella proline racemase protein A targets Tpl2 to promote IL-10 secretion for establishment of chronic infection

  • By

  • Huan Zhang

  • Xueyu Tao

  • Yuanzhi Wang

  • Yueli Wang

  • Huilin Hou

  • Xiaoyu Deng

  • Zhenyu Xu

  • Xujin Xia

  • Mingguo Xu

  • Zhen Wang

  • Changsuo Zhang

  • Zhumanov Kairat Toksanbaevich

  • Jinliang Sheng

  • Zhongchen Ma

  • Jihai Yi

  • Chuangfu Chen

  • June 9, 2026

  • 0 min

Share

Objective:

To explore the functions of B. melitensis M5–90 PrpA in macrophages, investigate the specific mechanisms of IL-10 production induction, and assess the immune response induced by the B. melitensis M5–90 prpA mutant in mice.

Key Findings:
  • PrpA induces IL-10 secretion in macrophages via the Tpl2-ERK signaling pathway.
  • Tpl2 deletion reduces macrophage bactericidal ability and cytokine levels (TNF-α, IL-1β, IL-10).
  • PrpA deletion increases IFN-γ levels, anti-Brucella IgG, and T cell counts in mice.
  • The B. melitensis M5–90 prpA mutant offers better protection against virulent Brucella melitensis M28 infection.
Interpretation:

Brucella PrpA enhances IL-10 production in macrophages, promoting bacterial survival and facilitating chronic infection.

Limitations:
  • The specific mechanisms of PrpA interaction with Tpl2 remain partially understood, which may hinder targeted therapeutic strategies.
  • Further studies are needed to fully elucidate the role of PrpA in immune modulation and its potential as a vaccine target.
Conclusion:

The findings suggest that targeting PrpA may provide critical insights for developing effective vaccines against brucellosis, potentially improving public health outcomes.

Original Source(s)

Brucella proline racemase protein A targets Tpl2 to promote IL-10 secretion for establishment of chronic infection

  • by Huan Zhang, Xueyu Tao, Yuanzhi Wang, Yueli Wang, Huilin Hou, Xiaoyu Deng, Zhenyu Xu, Xujin Xia, Mingguo Xu, Zhen Wang, Changsuo Zhang, Zhumanov Kairat Toksanbaevich, Jinliang Sheng, Zhongchen Ma, Jihai Yi, Chuangfu Chen

  • June 9, 2026

Related Content

Immune recovery following switch from EFV-based regimens to bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed immunological non-responders: a 144-week real-world cohort study in China

Maternal Respiratory Syncytial Virus Prefusion F Vaccination and Acute Respiratory Illness in Infants

Correction: Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation